Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Enliven Therapeutics Inc.

    NASDAQ: ELVN · Real-Time Price · USD
    23.53
    1.62 (7.39%)
    At close: Jun 16, 2025, 2:51 PM

    Enliven Therapeutics Statistics

    Share Statistics

    Enliven Therapeutics has 49.07M shares outstanding. The number of shares has increased by 4.18% in one year.

    Shares Outstanding

    n/a
    		 49.07M

    Shares Change (YoY)

    n/a
    		 4.18%

    Shares Change (QoQ)

    n/a
    		 0.3%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 32.22M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,602

    FTD / Avg. Volume

    n/a
    		 0.46%

    Short Selling Information

    The latest short interest is 6.5M, so 13.25% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.5M

    Short % of Shares Out

    n/a
    		 13.25%

    Short % of Float

    n/a
    		 20.7%

    Short Ratio (days to cover)

    n/a
    		 22.13

    Valuation Ratios

    The PE ratio is -11.9 and the forward PE ratio is -7.03. Enliven Therapeutics's PEG ratio is 1.99.

    PE Ratio

    n/a
    		 -11.9

    Forward PE

    n/a
    		 -7.03

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 13.1

    PB Ratio

    n/a
    		 3.42

    P/FCF Ratio

    n/a
    		 -14.46

    PEG Ratio

    n/a
    		 1.99
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Enliven Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 19.99, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 19.99

    Quick Ratio

    n/a
    		 19.99

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,435,870.97

    Employee Count

    n/a
    		 62

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -232K

    Effective Tax Rate

    n/a
    		 0.26%

    Stock Price Statistics

    The stock price has increased by 0.97% in the last 52 weeks. The beta is 0.95, so Enliven Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.95

    52-Week Price Change

    n/a
    		 0.97%

    50-Day Moving Average

    n/a
    		 18.44

    200-Day Moving Average

    n/a
    		 22.29

    Relative Strength Index (RSI)

    n/a
    		 60.37

    Average Volume (20 Days)

    n/a
    		 350,919

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -317K

    Operating Income

    n/a
    		 -104.55M

    Net Income

    n/a
    		 -89.02M

    EBITDA

    n/a
    		 -88.47M

    EBIT

    n/a
    		 -88.79M

    Earnings Per Share (EPS)

    n/a
    		 -1.89
    Full Income Statement

    Balance Sheet

    The company has 124.12M in cash and 0 in debt, giving a net cash position of 124.12M.

    Cash & Cash Equivalents

    n/a
    		 124.12M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -243.47M

    Total Assets

    n/a
    		 302.57M

    Working Capital

    n/a
    		 280.35M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -73.19M and capital expenditures -44K, giving a free cash flow of -73.24M.

    Operating Cash Flow

    n/a
    		 -73.19M

    Capital Expenditures

    n/a
    		 -44K

    Free Cash Flow

    n/a
    		 -73.24M

    FCF Per Share

    n/a
    		 -1.56
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ELVN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ELVN is $40, which is 82.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $40

    Price Target Difference

    n/a
    		 82.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Feb 24, 2023. It was a backward split with a ratio of 1:4.

    Last Split Date

    n/a
    		 Feb 24, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:4

    Scores

    Altman Z-Score

    n/a
    		 31.8

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist